Zobrazeno 1 - 10
of 45
pro vyhledávání: '"Alexandra Savell"'
Autor:
Pamela S. Becker, Michael D. Robbins, Peter Sabbatini, Stacey Chuma, Kalvis Hornburg, Kaitlen Reyes, Alexandra Savell, Patrick Henrick, Jacob Laubach, Kenneth C. Anderson, Paul G. Richardson, Romanos Sklavenitis-Pistofidis, Oksana Zavidij, Rachid Baz, Raymond P. Perez, Robert A. Redd, Chia-Jen Liu, Irene M. Ghobrial
This file contains the legends for the supplementary figures.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::403647a09b3635dce22c4f3b8c519b1a
https://doi.org/10.1158/1078-0432.22473741
https://doi.org/10.1158/1078-0432.22473741
Autor:
Pamela S. Becker, Michael D. Robbins, Peter Sabbatini, Stacey Chuma, Kalvis Hornburg, Kaitlen Reyes, Alexandra Savell, Patrick Henrick, Jacob Laubach, Kenneth C. Anderson, Paul G. Richardson, Romanos Sklavenitis-Pistofidis, Oksana Zavidij, Rachid Baz, Raymond P. Perez, Robert A. Redd, Chia-Jen Liu, Irene M. Ghobrial
Purpose:Ulocuplumab (BMS-936564) is a first-in-class fully human IgG4 monoclonal anti-CXCR4 antibody that inhibits the binding of CXCR4 to CXCL12.Patients and Methods:This phase Ib/II study aimed to determine the safety and tolerability of ulocupluma
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::54d7c946d4f8b2b3fdf89b50a1279664
https://doi.org/10.1158/1078-0432.c.6528591
https://doi.org/10.1158/1078-0432.c.6528591
Autor:
Pamela S. Becker, Michael D. Robbins, Peter Sabbatini, Stacey Chuma, Kalvis Hornburg, Kaitlen Reyes, Alexandra Savell, Patrick Henrick, Jacob Laubach, Kenneth C. Anderson, Paul G. Richardson, Romanos Sklavenitis-Pistofidis, Oksana Zavidij, Rachid Baz, Raymond P. Perez, Robert A. Redd, Chia-Jen Liu, Irene M. Ghobrial
The figures show that patients received 10 mg ulocuplumab could reach higher concentration peak and larger dose-corrected area under curve (both p < 0.001).
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::153ca41d7fcc6ab8e1b99fc0d6f3904f
https://doi.org/10.1158/1078-0432.22473753.v1
https://doi.org/10.1158/1078-0432.22473753.v1
Autor:
Pamela S. Becker, Michael D. Robbins, Peter Sabbatini, Stacey Chuma, Kalvis Hornburg, Kaitlen Reyes, Alexandra Savell, Patrick Henrick, Jacob Laubach, Kenneth C. Anderson, Paul G. Richardson, Romanos Sklavenitis-Pistofidis, Oksana Zavidij, Rachid Baz, Raymond P. Perez, Robert A. Redd, Chia-Jen Liu, Irene M. Ghobrial
This figure shows Absolute cell numbers in the peripheral blood of patients receiving 10mg/kg ulocuplumab (absolute count, cells/uL).
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::61f08c65058363e1de82e8b0fc83392e
https://doi.org/10.1158/1078-0432.22473744
https://doi.org/10.1158/1078-0432.22473744
Autor:
Pamela S. Becker, Michael D. Robbins, Peter Sabbatini, Stacey Chuma, Kalvis Hornburg, Kaitlen Reyes, Alexandra Savell, Patrick Henrick, Jacob Laubach, Kenneth C. Anderson, Paul G. Richardson, Romanos Sklavenitis-Pistofidis, Oksana Zavidij, Rachid Baz, Raymond P. Perez, Robert A. Redd, Chia-Jen Liu, Irene M. Ghobrial
This figure shows (A) Proportion of circulating CD34+ stem cells (% of living cells, all patients combined). (B) Proportion of circulating CD138+ myeloma cells (% of living cells, all patients combined) (C) Distribution of CD34+ stem cells in respond
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::64d55193434afd6c9a2660c69f9aed4d
https://doi.org/10.1158/1078-0432.22473750
https://doi.org/10.1158/1078-0432.22473750
Autor:
Pamela S. Becker, Michael D. Robbins, Peter Sabbatini, Stacey Chuma, Kalvis Hornburg, Kaitlen Reyes, Alexandra Savell, Patrick Henrick, Jacob Laubach, Kenneth C. Anderson, Paul G. Richardson, Romanos Sklavenitis-Pistofidis, Oksana Zavidij, Rachid Baz, Raymond P. Perez, Robert A. Redd, Chia-Jen Liu, Irene M. Ghobrial
This figure presents a consort diagram showing (A) the dose-escalation scheme for BMS-936564 (ulocuplumab), (B) the dose-expansion scheme, including Arms A & B, of the study and (C) Number of patients at each dose level in the phase I and II studies
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1b5a4c5a0bde393f0e59926e66f78ad8
https://doi.org/10.1158/1078-0432.22473756.v1
https://doi.org/10.1158/1078-0432.22473756.v1
Autor:
Jacqueline S. Garcia, Yael Flamand, Livius Penter, Michael Keng, Benjamin K. Tomlinson, Lourdes M. Mendez, Paul Koller, Nicole Cullen, Yohei Arihara, Kathleen Pfaff, Jacquelyn O. Wolff, Andrew M. Brunner, Ilene Galinsky, Asad Bashey, Joseph H. Antin, Corey Cutler, Vincent Ho, Brian A. Jonas, Marlise R. Luskin, Martha Wadleigh, Eric S. Winer, Alexandra Savell, Rebecca Leonard, Taylor Robertson, Matthew S. Davids, Howard Streicher, Scott J. Rodig, Jerome Ritz, Catherine J. Wu, Daniel J. DeAngelo, Donna Neuberg, Richard M. Stone, Robert J. Soiffer
Publikováno v:
Blood
Two articles in this week’s issue focus on the use of ipilimumab and decitabine for patients with myelodysplasia (MDS) and acute myeloid leukemia (AML) before and after hematopoietic stem cell transplantation (HSCT) for high-risk disease. In the fi
Autor:
Yoshinobu Konishi, Romanos Sklavenitis-Pistofidis, Hong Yue, Federico Ferrari, Robert A. Redd, Elizabeth D. Lightbody, Massimiliano Russo, Jacqueline Perry, Erica Horowitz, Anna V. Justis, Nader A. Shayegh, Alexandra Savell, Julia Prescott, Shohreh Varmeh, Radosław P. Nowak, Mark Hamilton, Daniel Auclair, Catherine R. Marinac, Lorenzo Trippa, Eric S. Fischer, Irene M. Ghobrial
Publikováno v:
Cancer Cell
Autor:
Matthew S. Davids, Robert J. Soiffer, Emma S. Hathaway, F. Stephen Hodi, Pavan Bachireddy, Magdalena Thurin, Vincent T. Ho, Wandi Zhang, Sarah Nikiforow, Nicoletta Cieri, Jerome Ritz, Stacey Gabriel, Mariano Severgnini, Aashna Jhaveri, X. Shirley Liu, Haesook T. Kim, Jingxin Fu, Kenneth J. Livak, Sacha Gnjatic, Scott J. Rodig, Alexandra Savell, Philippe Armand, Catherine J. Wu, Teddy Huang, Joseph H. Antin, Corey Cutler, Carrie Cibulskis, Livius Penter, Shuqiang Li, Howard Streicher, Donna Neuberg, Srinika Ranasinghe, Matthew Nazzaro, Yi Zhang, Emily M. Thrash, Helen X. Chen, John Koreth, Seunghee Kim-Schulze
Publikováno v:
Blood
Relapsed myeloid disease after allogeneic stem cell transplantation (HSCT) remains largely incurable. We previously demonstrated the potent activity of immune checkpoint blockade in this clinical setting with ipilimumab or nivolumab. To define the mo
Autor:
Yi Bin Chen, Edward D. Ball, Robert J. Soiffer, Vincent T. Ho, Pavan Bachireddy, Corey Cutler, David Avigan, Asad Bashey, Catherine J. Wu, Howard Streicher, Michael Mazzeo, Jerome Ritz, Alexandra Savell, Edwin P. Alyea, Frederick L. Locke, Haesook T. Kim, Philippe Armand, Caitlin Costello, Adrienne Anderson, Alex F. Herrera, Sarah Nikiforow, Rodrigo O. Maegawa, Alexander P. Boardman, Augustine Weber, Matthew S. Davids
Publikováno v:
Blood
Programmed cell death-1 (PD-1)/programmed death ligand-1 blockade may potentially augment graft-vs-tumor effects following allogeneic hematopoietic cell transplantation (alloHCT), but retrospective studies of anti–PD-1 therapy reported substantial